Follicular Lymphoma · line 2 · Rituximab + Lenalidomide (R²/AUGMENT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RITUXIMAB-LENALIDOMIDE-R2 |
| ID | IND-FL-2L-R2 |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | DIS-FL |
| Sources | SRC-AUGMENT-LEONARD-2019 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off (CHARTER §6.1). Aggressive-track chemo-free 2L for r/r FL. AUGMENT (Leonard 2019 JCO, PMID 30897038, PMC7035866). R² × 12 cycles q28d. Outcome data confirmed from AUGMENT full text (PMC7035866): PFS HR 0.46 (95% CI 0.34-0.62; p<0.001); median PFS 39.4 vs 14.1 mo. ORR 78% (95% CI 71-83%) R² vs 53% (95% CI 46-61%) R+placebo (IRC assessment). CR 34% (95% CI 27-41%) R² vs 18% (95% CI 13-25%) R+placebo. Lenalidomide mandatory REMS pregnancy-prevention program. VTE prophylaxis mandatory. Teratogenicity covered in do_not_do_en — no CI-PREGNANCY-TERATOGEN entity currently modeled.
Used By
Algorithms
ALGO-FL-2L- ALGO-FL-2L